LL-37
Overview
Research-use cationic cathelicidin peptide supplied for studies of innate immune signaling, host-defense pathways, and epithelial response models.
- Concentration
- 5 mg
- Stock
- In stock
Product details
LL-37 is a synthetic cationic cathelicidin peptide derived from hCAP18 and used in innate immune and epithelial signaling research models. Pattern lists this material for controlled laboratory research.
Research Targets: Microbial membrane interaction models, TLR signaling, chemotaxis pathways, epithelial immune signaling.
Key Feature: Human cathelicidin-derived peptide format for host-defense pathway research.
Research Focus Areas: Innate immune response models, epithelial barrier signaling, inflammatory pathway studies, wound-response models.
Common Models: Microbial membrane assays, epithelial and keratinocyte cell models, cytokine response assays.
Mechanistic Interests: Membrane interaction, TLR pathway markers, chemokine signaling, immunomodulatory response markers.
Use Boundary: Research use only; not for human or veterinary use; no diagnostic, therapeutic, or consumption use is implied.
Research context
Peptide guide
Open full guide- Guide profile
- Antimicrobial Peptide
- Composition
- 37-amino-acid cationic antimicrobial peptide (AMP) derived from the C-terminal cleavage product of human cathelicidin (hCAP18), the only cathelicidin found in humans
- Discovery
- Identified in 1995 during research on innate immune defense mechanisms as the active antimicrobial domain of human cathelicidin (hCAP18), expressed primarily in neutrophils, epithelial cells, and skin
- Research scope
- Preclinical research describes LL-37's antimicrobial, immunomodulatory, and wound-healing properties across multiple models
- Regulatory status
- No FDA approval; lacks large-scale human RCTs for therapeutic claims. Human data limited to small exploratory studies and in vitro/animal models
Safety context
- Hypersensitivity to LL-37 or components
- Caution in inflammatory dermatological conditions where LL-37 is already elevated (e.g., psoriasis, rosacea)
- Limited human safety data—use with medical supervision
Research-use notice: LL-37 is an investigational antimicrobial and immunomodulatory peptide with most support coming from preclinical and early exploratory research. It is not FDA-approved for therapeutic use, and human safety and efficacy data remain limited and indication-specific. Compounded formulations vary in quality and purity. LL-37's role in inflammatory skin conditions is complex and context-dependent, so clinical decisions require qualified medical oversight.
Full guide includes 10 reference entries.
One kit adds 10 vials to checkout.